US2010197646A1PendingUtilityA1
Solvent-based sterilisation of pharmaceuticals
Est. expiryFeb 19, 2022(expired)· nominal 20-yr term from priority
A61K 9/14Y10T428/2982A61K 9/0078A61P 11/06A61L 2/022A61L 2/18A61L 2/02A61L 2103/05
50
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A sterile composition of a pharmaceutical compound is prepared by combining solvent with a non-sterile pharmaceutical compound to form a solution and filtering to yield a sterile pharmaceutical compound, optionally removing all or part of the solvent, and under sterile conditions combining the compound with a pharmaceutically acceptable carrier.
Claims
exact text as granted — not AI-modified1 - 76 . (canceled)
77 . A method for preparing sterile budesonide comprising:
(i) dissolving non-sterile budesonide in a solvent to form a non-sterile budesonide solution; (ii) filtering the non-sterile budesonide solution with a sterile filter to produce a sterile budesonide solution; and (iii) removing the solvent from the sterile budesonide solution to produce a sterile budesonide powder.
78 . The method as defined in claim 77 wherein the sterile filter has a pore size of 0.2 μm or less.
79 . The method of claim 77 further comprising the step of reducing the particle size of the sterile budesonide powder to a mass mean diameter of less than 10 μm.
80 . The method of claim 79 wherein the particle size of the sterile budesonide powder is reduced to a mass mean diameter of 1-5μm.
81 . The method of claim 80 wherein the particle size of the sterile budesonide powder is reduced to a mass mean diameter of 2-3μm.
82 . The method of claim 77 wherein the steps of the method are conducted under low oxygen conditions.
83 . The method of claim 77 wherein the steps of the method are conducted under vacuum conditions.
84 . The method of claim 77 wherein the steps of the method are conducted under nitrogen conditions.
85 . The method of claim 77 wherein the steps of the method are protected from light.
86 . The method of claim 77 further comprising the step of packaging the sterile budesonide powder.
87 . The method of claim 86 wherein the step of packaging the sterile budesonide powder is performed under sterile conditions.
88 . The method of claim 77 wherein step (i) is conducted at room temperature.
89 . The method of claim 77 further comprising the step of heating the solvent to 30-50° C. prior to dissolving the non-sterile budesonide.
90 . The method of claim 77 wherein the solvent is removed under reduced pressure.
91 . The method of claim 77 wherein the solvent is removed under vacuum conditions.
92 . The method of claim 77 wherein the solvent is removed at a temperature of 40° C. or less.
93 . The method of claim 77 further comprising the step of combining the sterile budesonide powder with a pharmaceutically acceptable carrier.
94 . The method of claim 93 wherein the pharmaceutically acceptable carrier is sterile water.
95 . The method of claim 77 wherein the solvent is a Class 2 solvent selected from the group consisting of acetonitrile, chlorobenzene, chloroform, cyclohexane, 1,2-dichloroethane, dichloromethane, 1,2-dimethoxyethane, 1,4-dioxane, 2-ethoxyethanol, ethyleneglycol, formamide, hexane, methanol, 2-methoxyethanol, methylbutyl ketone, methylcyclohexane, N-methylpyrrolidone, nitromethane, tetrahydrofuran, toluene, 1,2-trichloroethene and xylene.
96 . The method of claim 77 wherein the solvent is a Class 3 solvent selected from the group consisting of acetone, anisole, 1-butanol, 2-butanol, butyl acetate, tert-butylmethyl ether, cumene, ethanol, ethyl acetate, ethyl ether, heptane, isobutyl acetate, isopropyl acetate, methyl acetate, 3-methyl-1-butanol, methylethyl ketone, methylisobutyl ketone, 2-methyl-1-propanol, pentane, 1-pentanol, 2-pentanol, 2-propanol, and propyl acetate.
97 . The method of claim 77 wherein the solvent comprises an alcohol.
98 . The method of claim 97 wherein the alcohol is ethyl alcohol, methyl alcohol or isopropyl alcohol.Join the waitlist — get patent alerts
Track US2010197646A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.